Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Pilot Study of Methylthioninium Chloride in Frontotemporal Dementia and Related Syndromes
2005-005915-13Phase 2Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylene blue in frontotemporal dementia (FTD), Frontotemporal Dementia with Parkinsonism (FTDP-17), primary progressive aphasia (PPA) and 2 more, sponsored by TauRx Therapeutics Ltd. Primary endpoint: Primary cognitive ability outcome. Started Apr 2006; status: completed.
02
Drugs
methylene blue
03
Conditions
frontotemporal dementia (FTD)Frontotemporal Dementia with Parkinsonism (FTDP-17)primary progressive aphasia (PPA)corticobasal degeneration (CBD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on 2005-005915-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005915-13.